Ablynx completes 40 million ($50 million) Series C venture capital
Ablynx, the pioneer in the discovery and development of Nanobodies , a novel class of antibody-derived therapeutic proteins, has announced the successful closing of its series C financing round raising 40 … 
Next Story: Kemia Closes Series C Financing
Previous Story: Investors pump $93 million into Adam Aircraft project
